Literature DB >> 2390425

The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990)

N Caporaso1, J R Idle.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2390425      PMCID： PMC1368288          DOI： 10.1111/j.1365-2125.1990.tb03756.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.

Authors:  T K Henthorn; J Benitez; M J Avram; C Martinez; A Llerena; J Cobaleda; T C Krejcie; R D Gibbons
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

2.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

3.  Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.

Authors:  N Caporaso; R B Hayes; M Dosemeci; R Hoover; R Ayesh; M Hetzel; J Idle
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

4.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  C J Speirs; S Murray; D S Davies; A F Biola Mabadeje; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

5.  Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

Authors:  I Roots; N Drakoulis; M Ploch; G Heinemeyer; R Loddenkemper; T Minks; M Nitz; F Otte; M Koch
Journal:  Klin Wochenschr       Date:  1988

6.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

7.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

8.  The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.

Authors:  N Caporaso; L W Pickle; S Bale; R Ayesh; M Hetzel; J Idle
Journal:  Genet Epidemiol       Date:  1989       Impact factor: 2.135

9.  Debrisoquine metabolism and genetic predisposition to lung cancer.

Authors:  M R Law; M R Hetzel; J R Idel
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640
  9 in total
  1 in total

1.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.